Patients with biallelic FAT1 inactivation experience a significantly shorter PFS of 2.4 months, compared to 10.1 months in ER+ breast cancer patients with FAT1 missense mutations and 11.3 months in patients with wild-type FAT1 [80]. This evidence concerns the gene FAT1 and breast cancer.